Niagen Bioscience, Inc. (FRA:OCD1)
4.740
-0.040 (-0.84%)
At close: Jan 30, 2026
Niagen Bioscience Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 64.14 | 44.51 | 27.17 | 20.29 | 28.02 | 16.5 |
Cash & Short-Term Investments | 64.14 | 44.51 | 27.17 | 20.29 | 28.02 | 16.5 |
Cash Growth | 98.90% | 63.80% | 33.93% | -27.59% | 69.84% | -11.36% |
Accounts Receivable | 8.51 | 7.77 | 5.23 | 8.48 | 5.23 | 2.69 |
Other Receivables | 0.6 | 0.9 | - | - | - | - |
Receivables | 9.11 | 8.67 | 5.23 | 8.48 | 5.23 | 2.69 |
Inventory | 18.79 | 9.19 | 14.53 | 14.68 | 13.6 | 11.68 |
Prepaid Expenses | 1.43 | 1.58 | 2.45 | 2.97 | 1.86 | 1.15 |
Restricted Cash | 0.15 | 0.15 | 0.15 | 0.15 | 0.2 | 0.2 |
Total Current Assets | 93.62 | 64.1 | 49.53 | 46.57 | 48.91 | 32.22 |
Property, Plant & Equipment | 3.86 | 3.45 | 4.54 | 6.32 | 7.36 | 4.43 |
Other Intangible Assets | 0.25 | 0.36 | 0.51 | 0.67 | 0.86 | 1.08 |
Other Long-Term Assets | 0.42 | 0.37 | 0.38 | 0.5 | 0.72 | 0.63 |
Total Assets | 98.14 | 68.28 | 54.96 | 54.06 | 57.84 | 38.36 |
Accounts Payable | 12.74 | 8.53 | 10.23 | 9.68 | 10.42 | 9.45 |
Accrued Expenses | 8.7 | 7.82 | 9.49 | 7.34 | 6.48 | 6.13 |
Current Portion of Leases | 0.98 | 0.99 | 0.7 | 0.7 | 0.55 | 0.62 |
Current Unearned Revenue | 0.29 | 0.61 | 0.2 | 0.16 | 0.16 | 0.28 |
Total Current Liabilities | 22.71 | 17.95 | 20.62 | 17.87 | 17.61 | 16.48 |
Long-Term Leases | 2.08 | 1.66 | 2.58 | 3.56 | 4.15 | 1.02 |
Long-Term Unearned Revenue | 2.67 | 2.58 | 3.31 | 3.96 | 4.35 | 4.44 |
Total Liabilities | 27.46 | 22.18 | 26.51 | 25.39 | 26.11 | 21.93 |
Common Stock | 0.08 | 0.08 | 0.08 | 0.07 | 0.07 | 0.06 |
Additional Paid-In Capital | 239.27 | 227.93 | 218.85 | 214.09 | 200.61 | 158.19 |
Retained Earnings | -168.66 | -181.91 | -190.46 | -185.49 | -168.95 | -141.83 |
Comprehensive Income & Other | -0.01 | -0 | -0 | -0 | -0 | -0 |
Shareholders' Equity | 70.68 | 46.09 | 28.46 | 28.67 | 31.73 | 16.42 |
Total Liabilities & Equity | 98.14 | 68.28 | 54.96 | 54.06 | 57.84 | 38.36 |
Total Debt | 3.06 | 2.65 | 3.28 | 4.26 | 4.7 | 1.64 |
Net Cash (Debt) | 61.08 | 41.86 | 23.9 | 16.03 | 23.32 | 14.86 |
Net Cash Growth | 108.11% | 75.16% | 49.05% | -31.24% | 56.91% | -12.04% |
Net Cash Per Share | 0.72 | 0.54 | 0.32 | 0.23 | 0.35 | 0.24 |
Filing Date Shares Outstanding | 80.09 | 77.92 | 75.48 | 75.02 | 68.49 | 66.92 |
Total Common Shares Outstanding | 79.92 | 77.5 | 75.15 | 74.75 | 68.31 | 62.06 |
Working Capital | 70.9 | 46.15 | 28.91 | 28.7 | 31.29 | 15.74 |
Book Value Per Share | 0.88 | 0.59 | 0.38 | 0.38 | 0.46 | 0.26 |
Tangible Book Value | 70.43 | 45.74 | 27.95 | 28 | 30.87 | 15.34 |
Tangible Book Value Per Share | 0.88 | 0.59 | 0.37 | 0.37 | 0.45 | 0.25 |
Machinery | - | 3.97 | 4.26 | 4.05 | 4.3 | 3.92 |
Construction In Progress | - | 0.09 | 0.01 | 0.17 | 0.09 | 0 |
Leasehold Improvements | - | 2.21 | 2.15 | 2.06 | 2.39 | 2.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.